GlaxoSmithKline plc operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GlaxoSmithKline plc with three other
pharmaceutical manufacturers in Europe:
sales of 46.58 billion Swiss Francs [US$51.01 billion]
of which 78%
was Innovative Medicines),
(37.37 billion Euros [US$44.86 billion]
of which 69%
was Pharmaceuticals), and
based in GERMANY
(41.40 billion Euros [US$49.70 billion]
of which 46%
During the year ended December of 2020, sales at
GlaxoSmithKline plc were £34.10 billion (US$47.43 billion).
a very small
increase of 1.0%
versus 2019, when the company's sales were £33.75 billion.
This was the fifth consecutive year of sales increases at GlaxoSmithKline plc
(and since 2015, sales have increased a total of 43%).
Sales of Consumer Healthcare saw an increase
that was more than double the company's growth rate: sales were up
11.5% in 2020, from
£9.00 billion to £10.03 billion.
Not all segments of GlaxoSmithKline plc experienced an increase in sales in 2020:
sales of Unallocated fell 41.7% to £28.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
GlaxoSmithKline plc also experienced decreases in sales in
Pharmaceuticals (down 2.8% to £17.06 billion)
Vaccines (down 2.4% to £6.98 billion)